The indices of patients’ health outcomes have historically included recurrence of symptoms, number of emergency visits, hospitalization and re-admission rates, morbidity, and mortality. As significant healthcare players, providers can influence these events, including the timeliness of diagnosis and disease management, the cost of treatment, access to health insurance, and medication adherence. Beyond healthcare availability and access, the ability of patients to adhere to providers’ treatment recommendations goes a long way to serve as a recipe for improving patient outcomes. Unfortunately, medication nonadherence has been prevalent, culminating in worsened health conditions, increased cost of care, and increased healthcare spending. This article provides some innovative ideas and good considerations for encouraging medication adherence. Improving providers’ and patients’ education and adopting active and passive communication, including consented reminders, could enhance compliance. Embracing partnerships between providers’ organizations and faith-based and community organizations could drive adherence. Adopting an income-based cap on out-of-pocket spending and adapting the physical properties, bioavailability, and dosage regimen of medications to accommodate diverse patient population preferences could encourage refills and compliance. Good medication adherence can culminate in improved patient outcomes.
Coronavirus disease 2019 (COVID-19) has extensively spread worldwide with high mortality. Besides vaccination, the United States Food and Drug Administration approved only one oral medication as a treatment. Medicinal plants with antiviral and immunomodulatory properties could be explored as complementary treatments for COVID-19. Ogbomosho is home to such plants traditionally used to treat infectious diseases in Nigeria, making it relevant in complementary medicine. An ethnobotanical survey of medicinal plants used to treat COVID-19 and related ailments, including cough and flu in Ogbomosho South and North Local Government Areas, Nigeria, was conducted using a semi-structured questionnaire. Information was obtained from 56 participants, consisting of different groups of individuals with native knowledge of medicinal plants, and ethnobotanical indices, including the frequency of citation (FC), relative frequency of citation (RFC), and fidelity level (FL) were computed. Twenty-six medicinal plants (17 families) were used to treat COVID-19, 31 (20 families) for cough, and 29 (19 families) for flu. The most cited plant was Zingiber officinale (FC = 10; RFC = 0.18; FL = 18%) for treating COVID-19, Citrus limon (FC = 13; RFC = 0.23; FL = 23%) for cough, and Zingiber officinale (FC = 9; RFC = 0.16; FL = 16%) for flu. Leaves were the most used plant part for treating COVID-19 and flu, while the bark was the most used for cough. Trees and herbs were the most cited plant growth forms. The herbal remedies were mostly prepared by decoction and infusion and were mainly administered orally. Further research should be conducted on the identified species for the scientific validation of their antiviral and immunomodulatory efficacies and safety for use.
Infectious diseases have been a significant challenge to health and wellbeing from ancient times, with substantial economic implications globally. Despite the advent of technology, infectious diseases continue to affect people of various social statuses and across geographical locations. Understanding some of the drivers of infectious diseases, antimicrobial resistance, vaccination, and vaccine hesitancy is a step towards thriving in the modern world, achieving fewer morbidities and mortalities, and adequately controlling future pandemics. Pharmacists are strategically placed as healthcare team members to promote early disease control through health education, advocacy, cross-professional and specialty collaboration, communal trust-building, research, and global unity. Not forgetting that infectious diseases in the modern world are about people and science, credible crisis communication during the early phases of disease outbreaks paves the way for well-informed guidance globally.
Empyema has rarely been associated with hepatic abscess. In patients with concurrent empyema and hepatic abscess, hepatic abscess drainage is usually required after drainage of the pleura. We present a rare case of a 91-year-old Caucasian man who presented with a 2-week history of productive cough, fever, shortness of breath, and generalized malaise. The patient was found to have concurrent streptococci empyema and hepatic abscess, and, interestingly, the hepatic abscess resolved after the drainage of the empyema and initiation of antibiotics.
(1) Background: The Coronavirus Disease 2019 (COVID-19) pandemic has raised concerns about the impact of underlying medical conditions on the health outcomes of people living with HIV (PLWH). This study aimed to assess how pre-existing chronic medical conditions affect the health outcomes of PLWH infected with COVID-19. (2) Methods: A retrospective study using data from the Minnesota Fairview network (1 January 2020–31 December 2022) was conducted. Fisher’s exact test, the Kruskal–Wallis rank-sum test, and ordinal logistic regressions with a Benjamini–Hochberg (BH) adjustment on p-values were used to assess the influence of chronic conditions on COVID-19 severity, adjusting for age and gender. (3) Results: Among 216 records, significant associations were found for a stroke, chronic kidney disease, lung disease, and neurologic conditions (p < 0.05). Type 1 diabetes was marginally significant (0.05 < p < 0.1). After adjusting for age and sex, a stroke (p = 0.0008, BH-adjusted p = 0.0044) and chronic kidney disease (p = 0.0003, BH-adjusted p = 0.0033) significantly increased the risk of severe COVID-19 outcomes. (4) Conclusions: Pre-existing medical conditions should be considered in the clinical management and public health interventions for PLWH infected with COVID-19. Tailored strategies are essential to mitigate the higher risk of severe outcomes in PLWH with specific chronic comorbidities.
Introduction: Obesity and age are established risk factors for breast cancer, but racial differences in the association between body mass index (BMI) and breast cancer incidence remain incompletely understood. This study examined the association between BMI and breast cancer incidence among non-Hispanic White and Black women in the VITamin D and OmegA-3 TriaL (VITAL) cohort and secondarily considered methodological issues that may arise when clinical trial data are analyzed observationally.